KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since InceptionNewsfile Corp • 09/29/26
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsGlobeNewsWire • 09/24/26
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ProgramGlobeNewsWire • 09/03/26
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ProgramGlobeNewsWire • 09/01/26
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineGlobeNewsWire • 04/21/26
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesGlobeNewsWire • 04/01/26
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveGlobeNewsWire • 03/30/26
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchBenzinga • 03/30/26
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug CandidateGlobeNewsWire • 03/18/26
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug CandidateNewsfile Corp • 03/18/26
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research AgentsNewsfile Corp • 03/11/26
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesGlobeNewsWire • 03/11/26
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”GlobeNewsWire • 03/04/26
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 12/04/25
KALA Stock Crashes 88% in a Month Following Eye Disorder Study FailureZacks Investment Research • 10/08/25
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to TradeZacks Investment Research • 08/13/25
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/25
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/06/25
Analyst Coverage Sparks Interest in These 4 Stocks Amid VolatilityZacks Investment Research • 07/25/25